 This is an open-label all people know the identity of the intervention, 2-panel, Phase 2, randomized study medication assigned to participants by chance study. The study will consist of 3 study phases: Screening Phase 5 weeks, an Open-label Treatment Phase 70 days for Panel 1 and 56 days for Panel 2, a Post-treatment Follow-up Phase 12 weeks after the actual end of treatment. Participants will receive a combination of the following treatments: Treatment A: SMV 150 milligram mg once daily; Treatment B: LDV 90 mg along with SOF 400 mg once daily; Treatment C: SOF 400 mg once daily. Participants will be randomly assigned to Panel 1 Treatment AC followed by Treatment AB and Panel 2 Treatment B followed by Treatment AB. The total study duration will be approximately 27 weeks for participants in Panel 1 and 25 weeks for participants in Panel 2. Participants will be primarily accessed for pharmacokinetic parameters. Participants safety will be monitored throughout the study. 